漱玉平民(301017) - 2022 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2022 was ¥7,822,931,715.52, representing a 47.00% increase compared to ¥5,321,639,204.67 in 2021[22] - The net profit attributable to shareholders for 2022 was ¥229,430,842.20, a significant increase of 99.64% from ¥114,924,330.81 in 2021[22] - The net profit after deducting non-recurring gains and losses was ¥220,035,639.01, up 115.18% from ¥102,254,571.67 in the previous year[22] - The basic earnings per share for 2022 was ¥0.57, a 90.00% increase from ¥0.30 in 2021[22] - The total assets at the end of 2022 reached ¥7,863,166,992.04, marking a 57.18% increase from ¥5,002,769,668.71 at the end of 2021[22] - The net assets attributable to shareholders increased by 18.08% to ¥2,231,277,500.21 from ¥1,889,588,905.46 in 2021[22] - The net cash flow from operating activities was ¥148,443,981.75, a decrease of 37.50% compared to ¥237,526,003.92 in 2021[22] - The weighted average return on equity for 2022 was 11.55%, an increase from 6.71% in 2021[22] Market Expansion and Operations - The company expanded its store network to 5,456 locations by the end of 2022, adding 2,115 new stores during the year, including 318 new direct-operated stores and 450 acquired stores[43] - The company operates in multiple provinces including Shandong, Liaoning, Heilongjiang, Fujian, and Henan, expanding its brand influence and market presence[36] - The company has been focusing on developing its wholesale franchise business since the end of 2019 to adapt to industry trends[39] - The company aims to enhance its online sales channels through a combination of B2C and O2O strategies to meet consumer demand for online pharmaceutical purchases[39] - The company is expanding its market presence in northern China, focusing on urban center stores and utilizing big data for site selection and customer flow analysis[62] Product Development and Sales - The company developed a total of 969 SKUs for its proprietary products, achieving a sales growth of 84% year-on-year, accounting for nearly 13% of total retail sales[54] - The "鹊华" brand of traditional Chinese medicine products saw sales increase by over 100% year-on-year due to innovative product development and marketing strategies[66] - New product lines introduced in 2022 contributed to a 25% increase in sales volume, particularly in the health supplement category[160] Financial Management and Investments - The total investment during the reporting period was CNY 839.47 million, a 30.49% increase compared to CNY 643.34 million in the previous year[97] - The company completed significant equity investments totaling approximately RMB 344.84 million during the reporting period[98] - The company raised a total of RMB 108.99502 million through public offerings and convertible bonds, with RMB 20.39 million utilized by the end of the reporting period[103] - The company has a total of RMB 793.5 million remaining in its fundraising account as of December 31, 2022[106] Corporate Governance and Compliance - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management to enhance the effectiveness of performance assessment systems[135] - The company emphasizes investor relations management through various communication methods, including phone calls, online performance briefings, and on-site research[136] - The company has set up an internal audit department to oversee related transactions, external guarantees, and the implementation of internal control systems, ensuring compliance and protecting shareholder rights[138] - The company maintains independence in assets, personnel, finance, institutions, and business operations from its controlling shareholders and actual controllers[139] Social Responsibility and Community Engagement - The company reported a total donation of approximately 17 million yuan for social welfare activities during the reporting period[196] - The company provided over 11 million yuan worth of masks and medical supplies as part of its social responsibility efforts[196] - In December 2022, the company distributed 320,000 acetaminophen tablets for free to pregnant women in Jinan and 6 million ibuprofen tablets benefiting 628,000 people in Shandong Province[196] - The company has established 127 donation points for the "Hope House" charity project, donating over 40,000 books to children in need[197] Employee Management and Development - The total number of employees at the end of the reporting period was 13,270, with 4,548 in the parent company and 8,722 in major subsidiaries[176] - The company has established a comprehensive training system, including various training programs for new employees, in-service staff, and management, to enhance professional skills and service quality[179] - The company plans to implement an employee stock ownership plan to enhance the alignment of interests between employees and owners, improving governance and competitiveness[178]